Ipratropiumbromide Vincion (Ipratropium Bromide)

Ipratropium bromide is an anticholinergic bronchodilator used to manage obstructive airway diseases.

• Chronic obstructive pulmonary disease (COPD): improves airflow and reduces breathlessness.
• Asthma: provides additional bronchodilation when used with other controllers.
• Chronic bronchitis: alleviates cough and sputum retention by relaxing airway smooth muscle.

• Ipratropium bromide acts as a competitive antagonist at muscarinic (M3) acetylcholine receptors on airway smooth muscle. By blocking acetylcholine‑induced bronchoconstriction, it promotes relaxation of the bronchial smooth muscle, leading to bronchodilation and improved airflow in the respiratory tract.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: reduced salivary secretion.
• Cough: irritation of the airway during inhalation.
• Throat irritation: mild soreness or scratchiness.
• Headache: transient mild headache.
• Dizziness: occasional light‑headedness.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Angioedema: swelling of face, lips or tongue.
• Severe allergic reaction: rash, itching, or anaphylaxis.
• Urinary retention: difficulty urinating in susceptible individuals.
• Tachycardia: rapid heart rate.

Before prescribing ipratropium bromide, clinicians should consider patient‑specific factors and monitor for potential risks.

• Assess respiratory status: ensure patient is stable before initiating therapy.
• Monitor anticholinergic effects: watch for dry mouth, urinary retention, or blurred vision.
• Use with caution in narrow‑angle glaucoma: anticholinergic activity may increase intra‑ocular pressure.
• Avoid in patients with known hypersensitivity to ipratropium or formulation excipients.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium bromide can interact with other medications that affect the cholinergic system or respiratory function.

Major Interactions (Avoid)

• Other anticholinergic bronchodilators: additive anticholinergic load may increase side‑effects.
• Potent anticholinergic agents (e.g., atropine): risk of severe anticholinergic toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑agonists (short‑acting or long‑acting): may mask bronchospasm signs.
• Antihistamines with anticholinergic properties: monitor for excessive dry mouth or urinary retention.
• Inhaled corticosteroids: assess for combined local irritation.